|
gptkbp:instanceOf
|
gptkb:drug
hypolipidemic agent
fibrate
|
|
gptkbp:approvedBy
|
gptkb:Europe
|
|
gptkbp:ATCCode
|
C10AB02
|
|
gptkbp:CASNumber
|
41859-67-0
|
|
gptkbp:chemicalFormula
|
C19H20ClNO4
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
gallbladder disease
severe liver dysfunction
severe renal dysfunction
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Mannheim
1970s
|
|
gptkbp:drugClass
|
fibrate
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bezafibrate
|
|
gptkbp:interactsWith
|
gptkb:insulin
gptkb:cyclosporine
statins
sulfonylureas
oral anticoagulants
|
|
gptkbp:KEGGID
|
D07541
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PPAR agonist
increases lipoprotein lipase activity
|
|
gptkbp:meltingPoint
|
188-190°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
361.8 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
Not recommended (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1422
39168
DB01393
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
rash
elevated liver enzymes
muscular dystrophy
gastrointestinal disturbances
|
|
gptkbp:synonym
|
Benzafibrate
Bezalip
Cedur
|
|
gptkbp:UNII
|
9IKM0A7TQY
|
|
gptkbp:usedFor
|
treatment of hypertriglyceridemia
treatment of hyperlipidemia
treatment of mixed dyslipidemia
|
|
gptkbp:bfsParent
|
gptkb:fibrates
|
|
gptkbp:bfsLayer
|
8
|